News
For Eyes Optical Takes Man to Places He's Never Been Before in Humorous New TV Campaign
August 2, 2010 7:36 pm | by Bio-Medicine.Org | CommentsNEW YORK , Aug. 2 /- As eyewear is increasingly being marketed as a beauty and fashion product, For Eyes Optical rolls out a series of new television commercials for those who have lost sight of the fact that there's no need to pay for illusions that glasses can't deliver. Using the...
DaVita 2Q profit rises as business expands
August 2, 2010 1:45 pm | by The Associated Press | CommentsKidney dialysis services provider DaVita Inc. said Monday its net income edged up 2 percent in the second quarter as it expanded and provided more treatments.DaVita said its earnings rose to $107.9 million, or $1.04 per share, from $105.8 million, or $1.02 per share, a year ago. The latest...
Economic reports give stocks big start for August
August 2, 2010 1:45 pm | by STEPHEN BERNARD - AP Business Writer - Associated Press | CommentsThe stock market began August with a huge rally after reports from around the world revived investors' faith in the global recovery.The Dow Jones industrial average rose 208 points Monday. All the major stock indexes rose about 2 percent.The first day of the month brought a stream of news that...
Nimodipine Oral Capsules: Medication Errors - IV Administration May Result in Death, Serious Harms
August 2, 2010 1:30 pm | by U.S. Food & Drug Administration | CommentsIV injection can result in cardiac arrest, severe falls in blood pressure, and other heart-related complications.
Jeffrey Sprague, Founder, Vertical Research Partners LLC
August 2, 2010 10:45 am | by Ken PrewittAssociated Press | Commentsxfdfw BLOOMBERG-SURVEILLANC-03
Momenta's generic drug approval aids Q2 finances
August 2, 2010 10:38 am | by Mass High Tech: The Journal of New England Technology | CommentsMomenta Pharmaceuticals Inc. is reporting that it narrowed its loss for the second quarter in the run up to its approval for its generic drug, enoxaparin, considered an alternative to Sanofi-Aventis’ Lovenox, an injectable drug to prevent and sometimes treat blood clots in the leg.
New studies question vascular multiple sclerosis hypothesis and treatment
August 2, 2010 10:38 am | by EurekAlert | Comments(Wiley-Blackwell) Two important new studies challenge the controversial hypothesis that venous congestion -- chronic cerebrospinal venous insufficiency (CCSVI) -- contributes to the development of multiple sclerosis. This theory has resulted in many MS patients receiving...
Haemonetics lands blood management deal
August 2, 2010 10:38 am | by Mass High Tech: The Journal of New England Technology | CommentsHaemonetics Corp. has formed a deal to provide its new blood management business intelligence portal, IMPACT Online, to member hospitals of Consorta Inc., a health-care group purchasing organization (GPO).
Repligen neuro research attracts major grant funding
August 2, 2010 10:37 am | by Mass High Tech: The Journal of New England Technology | CommentsWaltham biopharmaceuticals firm Repligen Corp. has received three grants, totaling in excess of $6 million, to apply to its HDAC inhibitor research for neurodegenerative diseases like Friedreich’s Ataxia and Huntington’s Disease.
NeoProfen (ibuprofen lysine) Injection: Recall and Shortage - Risk of Particulate Matter
August 2, 2010 10:30 am | by U.S. Food & Drug Administration | CommentsPotential for particulate matter to result in serious adverse effects.
Summary Box: Premiums drive Humana's 2Q growth
August 2, 2010 9:45 am | by The Associated Press | CommentsMEDICARE'S ADVANTAGE: Double-digit enrollment growth in lucrative Medicare Advantage plans helped lift Humana Inc.'s second-quarter profit 21 percent and the insurer raised its full-year outlook.BOTTOM LINE: The company earned $340.1 million, or $2 per share, up from $281.8 million, or $1.67 per...
Charles River Labs sees drop in Q2 numbers
August 2, 2010 9:41 am | by Mass High Tech: The Journal of New England Technology | CommentsJust days after announcing the cancellation of its planned $1.6 billion buy of China’s WuXi PharmaTech (Cayman) Inc., Charles River Laboratories International Inc. reports that it numbers for the second quarter of 2010 were down versus the same period last year.
Disparities in cardiovascular risk based more on socioeconomic status than race, ethnicity
August 2, 2010 9:41 am | by EurekAlert | Comments(University of California - Los Angeles) A new study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status. The researchers found that there are large differences in risk by socioeconomic status...
Dose optimization workshop helps reduce radiation dose associated with MDCT scans
August 2, 2010 9:41 am | by EurekAlert | Comments(American College of Radiology / American Roentgen Ray Society) Numerous radiology practices were able to significantly reduce the radiation dose associated with multi-detector computed tomography scans by participating in a one day dose optimization workshop provided by the Royal...
Insights from SUSS workshop on thin wafer handling at Semicon'West 2010
August 2, 2010 9:40 am | by I-Micronews | CommentsAt the recent Semicon exhibition in San Francisco Suss assembled a group of partners and technical and market experts (shown below) to discuss the status of 3D IC and specifically temporary bonding and thin wafer handling.
